About: Compassionate Use of Tocilizumab for Treatment of SARS-CoV-2 Pneumonia

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Compassionate Use of Tocilizumab for Treatment of SARS-CoV-2 Pneumonia Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Compassionate Use of Tocilizumab for Treatment of SARS-CoV-2 Pneumonia
Creator	Kumar, Sanjeev Chen, Peter Ammerman, Noriko Huang, Edmund Jordan, Stanley Oft, Jillian Tran, Hai Vo, Ashley Zabner, Rachel Smith, Ethan Bluen, Benjamin Gaultier, Cyril Ge, Shili Le, Catherine Lowenstein, Hayden Marks, Gregory Shane, Rita Toyoda, Mieko Zakowski, Phillip
Source	Medline; PMC
abstract	BACKGROUND: Preliminary data from SARS-CoV-2 pneumonia patients indicate that a cytokine storm may increase morbidity and mortality. Tocilizumab (anti-IL-6R) is FDA-approved for treatment of cytokine storm associated with chimeric antigen receptor T-cell therapy. Here we examined compassionate use of tocilizumab in patients with SARS-CoV-2 pneumonia. METHODS: We report on a single-center study of tocilizumab in hospitalized patients with SARS-CoV-2 pneumonia. All patients had confirmed SARS-CoV-2 pneumonia and oxygen saturations <90% on oxygen support with most intubated. We examined clinical and laboratory parameters including oxygen and vasopressor requirements, cytokine profiles, and C-reactive protein (CRP) levels pre- and post-tocilizumab treatment. RESULTS: Twenty seven SARS-CoV-2 pneumonia patients received one 400 mg dose of tocilizumab. IL-6 was the predominant cytokine detected at tocilizumab treatment. Significant reductions in temperature and CRP were seen post-tocilizumab. However, four patients did not show rapid CRP declines, of whom three had poorer outcomes. Oxygen and vasopressor requirements diminished over the first week post-tocilizumab. Twenty-two patients required mechanical ventilation; at last follow-up, 16 were extubated. Adverse events and serious adverse events were minimal, but two deaths (7.4%) occurred that were felt unrelated to tocilizumab. CONCLUSIONS: Compared to published reports on the morbidity and mortality associated with SARS-CoV-2, tocilizumab appears to offer benefits in reducing inflammation, oxygen requirements, vasopressor support, and mortality. The rationale for tocilizumab treatment is supported by detection of IL-6 in pathogenic levels in all patients. Additional doses of tocilizumab may be needed for those showing slow declines in CRP. Proof of efficacy awaits randomized, placebo-controlled clinical trials.
has issue date	2020-06-23(xsd:dateTime)
bibo:doi	10.1093/cid/ciaa812
bibo:pmid	32575124
has license	no-cc
sha1sum (hex)	18fdcf1a4b55d6b4fd0e275c59ec05394437de3c
schema:url	https://doi.org/10.1093/cid/ciaa812
resource representing a document's title	Compassionate Use of Tocilizumab for Treatment of SARS-CoV-2 Pneumonia
has PubMed Central identifier	PMC7337689
has PubMed identifier	32575124
schema:publication	Clin Infect Dis
resource representing a document's body	covid:18fdcf1a4b55d6b4fd0e275c59ec05394437de3c#body_text
is schema:about of	covid:arg/18fdcf1a4b55d6b4fd0e275c59ec05394437de3c named entity 'inflammation' named entity 'Pneumonia' named entity 'placebo controlled trial' named entity 'COVID' named entity 'CA, USA' named entity 'epidemic' named entity 'tocilizumab' named entity 'cytokines' named entity 'blood transfusions' named entity 'SARS-CoV-2' named entity 'inflammation' named entity 'tocilizumab' named entity 'cytokine' named entity 'pathogens' named entity 'arthritis' named entity 'IL-6' named entity 'IL-6' named entity 'epidemic' named entity 'IL-6' named entity 'humanized monoclonal antibody' named entity 'tocilizumab' named entity 'IL-6' named entity 'pneumonia' named entity 'IFN' named entity 'cytokine' named entity 'CAR' named entity 'transcriptional' named entity 'Tocilizumab' named entity 'ARDS' named entity 'CRP' named entity 'immune cell' named entity 'CRS' named entity 'ischemic injury' named entity 'ARDS' named entity 'United States' named entity 'severe pneumonia' named entity 'Roche-Genentech' named entity 'respiratory failure' named entity 'IL-10' named entity 'pneumonia' named entity 'SARS-CoV-2' named entity 'cytokine' named entity 'ARDS' named entity 'control group' named entity 'IL-6' named entity 'mechanical ventilation' named entity 'IL-6' named entity 'IL-6' named entity 'sepsis' named entity 'organ damage' named entity 'COVID' named entity 'IL-6R' named entity 'CRP' named entity 'T-cell' named entity 'IL-6R' named entity 'IL-6' named entity 'infection' named entity 'SARS-CoV-2' named entity 'case reports' named entity 'FDA' named entity 'epidemic' named entity 'IL-6'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software